New insights into therapeutic options for Pompe disease
Citations Over TimeTop 18% of 2011 papers
Abstract
Glycogen storage disease type II or Pompe disease (GSD II, MIM 232300) is a rare inherited metabolic myopathy caused by a deficiency of lysosomal acid α-glucosidase or acid maltase (GAA; EC 3.2.1.20), resulting in a massive lysosomal glycogen accumulation in cardiac and skeletal muscles. Affected individuals exhibit either severe hypotonia associated with hypertrophic cardiomyopathy (infantile forms) or progressive muscle weakness (late-onset forms). Even if enzyme replacement therapy has recently become a standard treatment, it suffers from several limitations. This review will present the main results of enzyme replacement therapy and the recent findings concerning alternative treatments for Pompe disease, such as gene therapy, enzyme enhancement therapy, and substrate reduction therapy.
Related Papers
- New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.(2014)
- → Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease(2020)38 cited
- Survival, Quality of Life and Effects of Enzyme Replacement Therapy in Adults with Pompe Disease(2013)
- → Experience with Adult Pompe Disease Treated at Home with Myozyme(2011)
- Enzyme replacement therapy for Pompe disease(2010)